Thomas Martin earned a medical degree at the University of Connecticut School of Medicine in Farmington, Connecticut. He completed internship and residency programs at Harbor-UCLA Medical Center in Torrance, California and a fellowship in hematology/oncology at UCSF Medical Center, where he was promoted to Adjunct Professor of Medicine in the Division of Hematology and Oncology. Dr. Martin later was appointed Assistant Professor of Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas. After several years, he returned as a faculty member at UCSF, where he currently serves as Associate Chief of the Hematology/Oncology Division and Professor of Clinical Medicine.
A Diplomate of the American Board of Internal Medicine with subspecialty certification in hematology, Dr. Martin is a member of the American Society for Blood and Marrow Transplantation, the American Society of Clinical Oncology, and the American Society of Hematology. He serves as Director of the Hematology Malignancies Research Committee and Co-Lead for the Cancer Immunology and Immunotherapy Program at UCSF.
Dr. Martin’s research interests include investigating novel treatments for multiple myeloma. This includes early-phase trials of new drugs, novel combinations, and therapeutics to use with bone marrow transplantation. He has a special interest in antibody therapy for myeloma and has been involved in studies assessing the efficacy of CD38 antibody combinations in newly diagnosed as well as relapse and refractory multiple myeloma. He is currently investigating the use of antibody drug conjugates and dual targeted “bispecific” antibodies as well as chimeric antigen receptor T-cells in RRMM. Dr Martin leads the Immunotherapy Committee for the International Myeloma Foundation (IMF) and Directs the Transplant and Cell Therapy Clinical Program at UCSF. The Dr. Martin has authored numerous articles in the peer-reviewed literature. Additionally, he is a teacher, mentor, and a frequent invited speaker.
